NORSTELLA, CITELINE ANNOUNCE AGREEMENT TO MERGE COMPANIES

KUALA LUMPUR, June 29 (Bernama) -- Norstella, an organisation that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)—a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance—have announced an agreement to merge the companies.

By uniting Norstella, which comprises four prominent pharmaceutical solutions providers—Evaluate, MMIT, Panalgo and The Dedham Group—with Citeline, the combined company will be well positioned to help life sciences companies reach patients faster by providing clients with the intelligence and answers they need from early clinical development through to commercialisation.

This move reflects the shared goal of becoming an end-to-end solution provider, helping patients access life-saving therapies.

“Accelerating innovation and ensuring that every patient gets the therapy that they need is our North Star,” said Norstella CEO Mike Gallup in a statement. “By bringing clinical and commercial intelligence together—along with real-world data—the combined company will be well positioned to deliver on its mission.”

Together, Norstella and Citeline will play a critical role in helping pharmaceutical manufacturers plan for and overcome barriers to access, not just during clinical trials but at every stage in the drug development life cycle.

Citeline’s solutions, including its portfolio of clinical trial products, provide insights that improve the speed and efficiency of clinical trials and reduce risk.

Now, the Citeline solutions—along with MMIT’s PAR data and other complementary Norstella data assets—can be powered by Panalgo’s Instant Health Data Analytics platform to provide transformative answers that will improve workflow and decision-making and, ultimately, help products get to market and to patients quicker than ever before.

“At Citeline, our mission is to accelerate the connection of treatments to patients and patients to treatments. Ultimately, this marriage of commercial and clinical capabilities will advance the mission and enable the pharmaceutical C-suite to manage portfolio strategy like never before,” said Ramsey Hashem, CEO, and Jay Nadler, Executive Chair, of Citeline.

The merger is expected to close in the second half of 2022 subject to customary closing conditions and regulatory approvals.

-- BERNAMA